American Cancer Society Updates Prostate Cancer Screening Guidelines for First Time Since 2010
The American Cancer Society has issued its first prostate cancer screening guidelines update since 2010, recommending regular PSA blood testing for eligible men, starting at age 50 and earlier for higher-risk men.
Newsnibs Staff
- 2026-11-15
- Updated 9:15 PM UTC
The American Cancer Society (ACS) this week issued updated prostate cancer screening guidelines. They replace the earlier "shared decision-making" approach, in which men decided on testing after a risk-benefit discussion with a clinician, with an explicit recommendation of regular screening for eligible men. Sources describe it as the group's first update since 2010.
Men at average risk are advised to have a prostate-specific antigen (PSA) blood test every two years from age 50 to 69. Men at higher risk, including Black men and those with a family history of the disease, are advised to start earlier and be tested more often. Annual screening from age 45 is the figure given for those groups, and some accounts carry it through age 69. A father, brother or son with a prostate cancer diagnosis is enough to move the start to 45. The guidelines recommend against the digital rectal exam as a screening tool, citing the PSA test's greater effectiveness.
Accounts of the guidance for older men differ. For ages 70 to 74, some describe a recommendation to continue screening, while others say men should discuss continuing with their provider. Routine screening is not recommended from 75 on, though one account says men with previously elevated PSA results are an exception. Another describes the cutoff as men 75 to 80 or with a life expectancy under 10 years. The stated reason is that the harms of follow-up procedures are likely to outweigh the benefits at those ages. Clinicians are to make sure patients understand the potential benefits, limitations and harms before testing goes ahead.
The update draws on a European study dating from 2009 that found PSA screening reduced the risk of dying from prostate cancer by 13%. One account of the research holds that flaws in a concurrent U.S. trial had obscured that benefit. The U.S. Preventive Services Task Force has not changed its 2018 guidelines, which tell patients to consult their doctors in deciding whether to be screened.
Dr. Andrew Wolf, a physician at the University of Virginia and an author of the new guidelines, said the balance of benefit and harm used to be unclear because most prostate cancers grow slowly and overtreatment is a risk. The new guidelines, he said, reflect advances in avoiding unnecessary procedures, and the approach has been shown to reduce the risk of dying from the disease. Dr. Robert Smith, who is associated with the ACS, said better medical approaches now allow detection of lethal tumors while sparing men unnecessary intervention for slow-growing cancers, which can be managed with active surveillance. Wolf also said Black men face roughly a two-thirds higher risk of developing prostate cancer than white men, and that most insurers are likely to cover the recommended testing.
Prostate cancer is the second most deadly cancer for men in the United States, and the ACS has pointed to significant racial and socioeconomic disparities in diagnosis. Figures for annual diagnoses vary, from more than 300,000 Americans a year to an ACS estimate of more than 333,000 men in 2026, with about 36,000 deaths expected. The five-year relative survival rate for localized prostate cancer is nearly 100%. The ACS expects the new measures to save lives by finding tumors before they spread.
Dr. Ash Tewari, who chairs the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai in New York City, said, "Men think it is going to happen to someone else." Tewari and Mount Sinai have deployed mobile screening units, including the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit, which first launched in the city in 2022. Actress Brooke Shields directed a public service announcement promoting early detection. Her father, Frank, died of prostate cancer in 2003. The Million Strong Men Initiative aims to screen more than one million men.
In Iowa, the state cancer registry estimates 3,100 men will be diagnosed with prostate cancer in 2026, or 14.3% of all new cancer diagnoses there. Dr. Matthew Ferroni of Mercy Medical Center's Hall-Perrine Cancer Center and Dr. Jonathan Rippentrop of Physicians' Clinic of Iowa Urology said advances in MRI imaging, biomarker testing and treatment have made routine screening more effective and less damaging than before. Both said the change simplifies the process for primary care providers, much like routine cholesterol checks, and is expected to increase early detection and preventive care visits.
Photo by Testalize.me on Unsplash